Vedolizumab

Clinical Use

Monoclonal antibody:
Treatment of ulcerative colitis and Crohn’s disease

Drug interactions

Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.

Metabolism

The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible.